Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA), a clinical-stage biopharmaceutical company focused on developing medicines for intracellular targets, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Dipal Doshi will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET).

The presentation will be accessible via live webcast on the company's Investor Relations website, with a replay available for 30 days following the event. Entrada's mission centers on transforming patient lives by creating innovative treatments that can reach previously inaccessible intracellular targets.

News Market Reaction

-7.32%

1 alert

-7.32% News Effect

On the day this news was published, TRDA declined 7.32%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET).

A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45 and 50 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Investor and Media Contact
Caileigh Dougherty
Head of Investor Relations & Corporate Communications
cdougherty@entradatx.com

FAQ

When is Entrada Therapeutics (TRDA) presenting at the 2025 J.P. Morgan Healthcare Conference?

Entrada Therapeutics will present on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET).

How can investors access Entrada Therapeutics' (TRDA) J.P. Morgan Healthcare Conference presentation?

Investors can access the live webcast through Entrada's Investor Relations website at https://ir.entradatx.com. A replay will be available for 30 days after the event.

What is Entrada Therapeutics' (TRDA) main focus in drug development?

Entrada Therapeutics focuses on developing a new class of medicines that can engage intracellular targets that were previously considered inaccessible.

How long will the replay of Entrada's (TRDA) J.P. Morgan Healthcare Conference presentation be available?

The webcast replay will be available for 30 days following the presentation.